“Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program”, J of Skin, vol. 9, no. 4, p. s583, Jul. 2025, doi: 10.25251/ed52rz19.